Zobrazeno 1 - 10 of 20 pro vyhledávání: '"Michel Van Speybroeck"'
3
Akademický článek
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
Autor: Julio Ramírez, Pascal Richette, Alen Zabotti, Sarah Ohrndorf, Elke Theander, Marijn Vis, William Tillett, May Shawi, Wim Noël, Marlies Neuhold, Michel van Speybroeck, Miriam Zimmermann, Alexa Kollmeier
Publikováno v: RMD Open, Vol 9, Iss 1 (2023)
Objectives Psoriatic arthritis (PsA) phenotypes are typically defined by their clinical components, which may not reflect patients’ overlapping symptoms. This post hoc analysis aimed to identify hypothesis-free PsA phenotype clusters using machine
Externí odkaz: https://doaj.org/article/420c72b2b3b04638a7ce97c7405459cb
Zobrazit plný text záznamu
5
P180 Minimal disease activity response patterns in bio-naïve patients with psoriatic arthritis treated with guselkumab: a machine learning analysis
Autor: Alen Zabotti, Sarah Ohrndorf, William Tillett, Marlies Neuhold, Michel van Speybroeck, Elke Theander, Christine Contré, Mohamed Sharaf, May Shawi, Michelle Perate, Alexa Kollmeier, Pascal Richette
Publikováno v: Rheumatology. 62
Background/Aims Guselkumab, a human monoclonal antibody targeting the interleukin-23 p19 subunit, demonstrated joint and skin efficacy in patients with PsA in the Phase III DISCOVER-1/-2 trials. MDA, a multi-domain composite outcome, is a clinically
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d038c3923f2d4976166c1c5114c19ccd
https://doi.org/10.1093/rheumatology/kead104.221
Zobrazit plný text záznamu
8
Haematology Outcomes Network in Europe (HONEUR)-A collaborative, interdisciplinary platform to harness the potential of real-world data in hematology
Autor: Kristina Bardenheuer, Michel Van Speybroeck, Clare Hague, Enkeleida Nikai, Martin Price
Publikováno v: European journal of haematologyREFERENCES. 109(2)
There remains a need to optimize treatments and improve outcomes among patients with hematologic malignancies. The timely synthesis and analysis of real-world data could play a key role.The Haematology Outcomes Network in Europe (HONEUR) is a federat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffead65a58b9b9b09005bd9275e9a938
https://pubmed.ncbi.nlm.nih.gov/35460296
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje